Please assess the completion status of the following clinical trial:

Trial Title: Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ grade 2 oral mucositis related to chemotherapy for cancer~* Ability to understand and the willingness to review and sign a written informed consent document.~* ≥ 18 years of age~* Willingness to use adequate contraception prior to study entry, for the duration of study participation and for 30 days after the last dose for women of child-bearing potential and men~Exclusion Criteria:~* Current use of therapeutic doses of anticoagulants such as warfarin or antiplatelet agents (prophylactic doses and agents are acceptable)~* Biliary tract obstruction or cholelithiasis~* History of gastric or duodenal ulcers or hyperacidity syndromes~* AST or ALT \> 2 x ULN~* Total bilirubin ≥ 2 x ULN~* INR \> 1.5~* Previous stem cell transplant (allogeneic or autologous)~* Preexisting oral disease, such as active oral infection, trauma to the oral mucosa or oral - ulceration prior to chemotherapy~* Known allergy/hypersensitivity to curcumin, yellow food coloring, or other members of the - Zingiberaceae (ginger) family~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mouthwash-standard pharmacy preparation (Type: ACTIVE_COMPARATOR): Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine.
- Curcumin (Type: EXPERIMENTAL): Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).
- Curcumin-MTD (Type: OTHER): Curcumin (BCM-95) administered by ingested mouth rinse. A total of 12-15 subjects will be in this arm to determine maximum tolerated dose (MTD).~There will be 3 participant at each of 4 does levels (0.33g, 1g, 2g, 3g) per rinse, three times daily for 4-6 weeks. (additional 3 subjects if a dose-limiting toxicity occurs)

Based on this trial design, predict the completion outcome and termination type (if applicable).